Compare TREX & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREX | TVTX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 1998 | 2013 |
| Metric | TREX | TVTX |
|---|---|---|
| Price | $38.93 | $44.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | ★ $49.53 | $40.62 |
| AVG Volume (30 Days) | 1.5M | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ 1.78 | N/A |
| Revenue | ★ $1,174,267,000.00 | N/A |
| Revenue This Year | $5.09 | $44.76 |
| Revenue Next Year | $6.24 | $35.51 |
| P/E Ratio | $22.14 | ★ N/A |
| Revenue Growth | ★ 1.98 | N/A |
| 52 Week Low | $29.77 | $13.88 |
| 52 Week High | $68.78 | $43.31 |
| Indicator | TREX | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.09 | 71.11 |
| Support Level | $38.92 | $32.62 |
| Resistance Level | $44.84 | N/A |
| Average True Range (ATR) | 1.39 | 1.92 |
| MACD | -0.30 | 0.24 |
| Stochastic Oscillator | 8.76 | 90.20 |
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.